Venetoclax Plus Azacitidine

A Phase I/II Study of Venetoclax in Combination With Azacitidine in Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
58 patients (estimated)
Sponsors
MD Anderson Cancer Center
Collaborators
National Cancer Institute (NCI), Genentech
Tags
BCL-2 Inhibitor
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1508
NCT Identifier
NCT04550442

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.